These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 27686644

  • 1. [New progress of castration-resistant prostate cancer immunotherapy].
    Liu JP, Wang H.
    Zhonghua Wai Ke Za Zhi; 2016 Oct 01; 54(10):787-791. PubMed ID: 27686644
    [Abstract] [Full Text] [Related]

  • 2. Immunotherapy in prostate cancer: challenges and opportunities.
    Noguchi M, Koga N, Moriya F, Itoh K.
    Immunotherapy; 2016 Oct 01; 8(1):69-77. PubMed ID: 26642100
    [Abstract] [Full Text] [Related]

  • 3. [Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatment].
    Djurhuus SS, Brasso K, Berg KD, Iversen P, Røder MA.
    Ugeskr Laeger; 2015 May 11; 177(20):. PubMed ID: 25967247
    [Abstract] [Full Text] [Related]

  • 4. Role of immunotherapy in castration-resistant prostate cancer (CRPC).
    Suárez C, Morales-Barrera R, Ramos V, Núñez I, Valverde C, Planas J, Morote J, Maldonado X, Carles J.
    BJU Int; 2014 Mar 11; 113(3):367-75. PubMed ID: 23650874
    [Abstract] [Full Text] [Related]

  • 5. [Current status and prospects of immunotherapy for castration-resistant prostate cancer].
    Yatsuda J, Eto M.
    Nihon Rinsho; 2014 Dec 11; 72(12):2174-8. PubMed ID: 25518354
    [Abstract] [Full Text] [Related]

  • 6. [Immunotherapy in castration resistant prostate cancer.].
    Miñana López B, Villacampa Aubá F, de Fata Chillón FR, Ancizu Markert FJ, García Cortés A, Doménech López P, Chiva San Román S, Velis Campillo JM, Díez-Caballero Alonso F, Robles García JE, Rosell Costa D, Pascual Piédrola JI.
    Arch Esp Urol; 2018 Sep 11; 71(8):685-695. PubMed ID: 30319128
    [Abstract] [Full Text] [Related]

  • 7. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG, Gelpi-Hammerschmidt F, Kundavram C.
    Can J Urol; 2014 Apr 11; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.
    Yoshimura K, Minami T, Nozawa M, Kimura T, Egawa S, Fujimoto H, Yamada A, Itoh K, Uemura H.
    Eur Urol; 2016 Jul 11; 70(1):35-41. PubMed ID: 26782346
    [Abstract] [Full Text] [Related]

  • 10. Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer.
    Saad F, Miller K.
    Urology; 2015 May 11; 85(5):976-986. PubMed ID: 25709051
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Updated treatments of castration-resistant prostate cancer].
    Wei YF, Gu XJ, Zhu QY.
    Zhonghua Nan Ke Xue; 2016 May 11; 22(5):455-61. PubMed ID: 27416673
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Current management of advanced and castration resistant prostate cancer.
    Gomella LG, Petrylak DP, Shayegan B.
    Can J Urol; 2014 Apr 11; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer.
    Benidir T, Hersey K, Finelli A, Hamilton R, Joshua AM, Kulkarni G, Zlotta A, Fleshner N.
    Urol Oncol; 2018 May 11; 36(5):240.e13-240.e20. PubMed ID: 29454590
    [Abstract] [Full Text] [Related]

  • 18. Navigating the evolving therapeutic landscape in advanced prostate cancer.
    Crawford ED, Petrylak D, Sartor O.
    Urol Oncol; 2017 May 11; 35S():S1-S13. PubMed ID: 28283376
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.
    Garcia JA, Dreicer R.
    Oncology (Williston Park); 2011 Mar 11; 25(3):242-9. PubMed ID: 21548467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.